Hansa Biopharma AB (publ) (HNSA) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Hansa Biopharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.879 Good day and welcome to the HANSA Biopharma Quarter 3 2025 Results Conference Call. 00:00:05.879 -- 00:00:08.383 All participants will be in listen-only mode. 00:00:08.383 -- 00:00:12.128 Should you need assistance, please signal a conference specialist by pressing the star 00:00:12.128 -- 00:00:17.316 key followed by zero. After today's presentation, there will be an opportunity to ask 00:00:17.316 -- 00:00:22.403 questions. To ask a question, you may press star then one on your touchtone phone. 00:00:22.403 -- 00:00:25.347 To withdraw your question, please press star then two. 00:00:25.347 -- 00:00:28.128 Please note this event is being recorded. 00:00:28.128 -- 00:00:34.033 I would now like to turn the conference over to Hansa Biopharma CEO, Renée Aguiar-Lucander. 00:00:34.033 -- 00:00:36.473 Please go ahead. 00:00:36.936 -- 00:00:40.839 Thank you very much, Operator. Good afternoon, good morning. 00:00:40.839 -- 00:00:45.143 Welcome to the Hansa Biopharma conference called Review Q3 and results for the first 00:00:45.143 -- 00:00:47.845 nine months of 2025. I'm Renée 00:00:47.845 -- 00:00:49.426 Aguiar-Lucander, 00:00:49.426 -- 00:00:55.111 CEO for Hansa Biopharma, and joining me today is Evan Ballantyne, CFO, 00:00:55.111 -- 00:00:59.582 Richard Philipson, Chief Medical Officer, and Maria Torrenson, Chief Operating Officer 00:00:59.582 -- 00:01:01.765 and President of the U.S. 00:01:01.765 -- 00:01:04.786 Please turn to slide two. 00:01:04.989 -- 00:01:08.192 Please allow me to just quickly draw your attention to the fact that we will be making 00:01:08.192 -- 00:01:12.357 forward-looking statements during the presentation, and you should therefore apply appropriate 00:01:12.357 -- 00:01:14.059 caution. 00:01:14.059 -- 00:01:1...